This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.
Aufreinigung
Affinity chromatography
Immunogen
Synthetic peptide derived from the human SET protein
2PP2A antikoerper, I2PP2A antikoerper, IGAAD antikoerper, IPP2A2 antikoerper, PHAPII antikoerper, TAF-I antikoerper, TAF-IBETA antikoerper, 2610030F17Rik antikoerper, 5730420M11Rik antikoerper, AA407739 antikoerper, I-2PP2A antikoerper, StF-IT-1 antikoerper, 2pp2a antikoerper, i2pp2a antikoerper, igaad antikoerper, ipp2a2 antikoerper, phapii antikoerper, set antikoerper, set-a antikoerper, set-b antikoerper, taf-ibeta antikoerper, wu:fb30g11 antikoerper, wu:fd16c08 antikoerper, SET nuclear proto-oncogene antikoerper, SET nuclear oncogene antikoerper, SET translocation antikoerper, SET nuclear proto-oncogene L homeolog antikoerper, SET nuclear proto-oncogene b antikoerper, SET antikoerper, Set antikoerper, LOC403555 antikoerper, set.L antikoerper, setb antikoerper
Hintergrund
Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I